skip to content

Clinical Trials

MainTitle

Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

This study has been completed
Sponsor
Hoffmann-La Roche


Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier
NCT00002143

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: April 1999
History of Changes
Purpose

Purpose

To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.

Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.

Condition Intervention Phase
HIV Infections
Psoriasis

Drug : Acitretin
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 30

Detailed Description:

Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment continues for a total of 20 weeks. Patients are followed every 2 weeks.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 55 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria
Concurrent Medication:
Allowed:

  • Any nondermatologic medication.

  • Patients must have:
  • HIV infection.
  • Psoriasis involving at least 10 percent of body surface.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002143

Locations

United States, New York
Beth Israel Med Ctr
New York, New York, United States, 10003

Sponsors and Collaborators

Hoffmann-La Roche
More Information

More Information


Responsible Party: Hoffmann-La Roche  
ClinicalTrials.gov Identifier: NCT00002143   History of Changes  
Other Study ID Numbers: 239A  
  65-93(2)  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Psoriasis
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Acitretin

Additional relevant MeSH terms:
HIV Infections
Psoriasis
Acitretin

ClinicalTrials.gov processed this data on October 16, 2017
This information is provided by ClinicalTrials.gov.